Azilsartan medoxomil: opportunities and prospects in diabetes mellitus
https://doi.org/10.18705/1607-419X-2021-27-2-247-254
Abstract
Current data on the prevalence of hypertension and diabetes mellitus (DM) are presented. Concomitant DM complicates the course of cardiac diseases, affecting the effectiveness of antihypertensive therapy. Along with high blood pressure, lipid and carbohydrate metabolism parameters should be corrected. Nephroprotection is also important in these patients. These goals are achievable due to the pleiotropic effects of some drugs. The analytical paper reviews the pleiotropic organoprotective effects of the antihypertensive drug azilsartan medoxomil. The data on its antihypertensive efficacy versus other angiotensin II receptor blockers are presented. In addition, the results of clinical trials in patients with various components of the metabolic syndrome (obesity, dyslipidemia, hyperglycemia) and DM are described.
About the Authors
A. M. Kochergina
Kemerovo State Medical University; Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Anastasia M. Kochergina, MD, PhD, Assistant, Department of Cardiology and Cardiovascular Surgery; Researcher Staff
6 Sosnoviy bul., Kemerovo, 650002 Russia
O. L. Barbarash
Kemerovo State Medical University; Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Olga L. Barbarash, MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Chief, Department of Cardiology and Cardiovascular Surgery; Director
Kemerovo
References
1. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A et al. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J. 2019; 40(25):2006–2017. doi:10.1093/eurheartj/ehz373
2. Rotar OP, Tolkunova KM, Solntsev VN, Erina AM, Boyarinova MA, Alieva AS et al. May measurement month 2019: adherence to treatment and hypertension control in Russia. Russian Journal of Cardiology. 2020;25(3):98–108. doi:10.15829/1560-4071-2020-3-3745. In Russian.
3. Shalnova SA, Drapkina OM. Contribution of the ESSE-RF study to preventive healthcare in Russia. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2020;19(3):209–215. doi:10.15829/1728-8800-2020-2602. In Russian.
4. Morozova TE, Andrushchishina TB. Arterial hypertension in patients with diabetes mellitus: an individualized choice of antihypertensive medications. Russian Journal of Cardiology. 2011;16(2):72–77. doi:10.15829/1560-4071-2011-2. In Russian.
5. Kobalava ZhD, Konradi AO, Nedogoda SV, Arutyunov GP, Baranova EI, Barbarash OL et al. Russian society of cardiology position paper on 2018 guidelines of the European society of cardiology/European society of arterial hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;23(12):131–142. doi:10.15829/1560-4071-2018-12-131-142. In Russian.
6. Подзолков В. И., Брагина А. Е., Ишина Т. И., Брагина Г. И., Васильева Л. В. Нефропротективная стратегия в лечении артериальной гипертензии как современная общемедицинская задача. Российский кардиологический журнал. 2018;(12):107–118. doi:10.15829/1560-4071-2018-12
7. Cosentino F, Grant PJ, Aboyans V, Bailey GJ, Ceriello А, Delgado V et al. Leeds institute of cardiovascular and metabolic medicine, university of Leeds/ Leeds Teaching Hospitals NHS Trust, LIGHT Laboratories, Clarendon Way. Russian Journal of Cardiology. 2020;25(4):3839. doi:10.15829/1560-4071-2020-3839. In Russian.
8. Clinical guidelines. Algorithms of specialized diabetes care. specialized diabetes care. 9nd ed. Dedov II, Shestakova MV, Mayorov AYu, eds M., 2019. URL: https://diabetmed.net/wp-content/uploads/2019/12/12211-29550-6-PB.pdf. In Russian.
9. Evdokimova AG, Golikova AA, Striuk RI, Lobanova EG. Modern aspects of diabetes mellitus type 2 treatment in cardiology practice (in the context of EASD/ADA consensus and Russian guidelines). Consilium Medicum. 2019;21(5):69–77. doi:10.26442/20751753.2019.5.190449. In Russian.
10. Shalnova SA, Konradi AO, Balanova YUA, Deev AD, Imaeva AE, Muromtseva GA et al. What factors do influence arterial hypertension control in Russia. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2018;17(4):53–60. doi:10.15829/1728-8800-2018-4-53-60. In Russian.
11. Likhodey NV, Kalashnikova MF, Likhodey EM, Fadeyev VV. Analysis of the factors that prevent adherence to treatment in patients with diabetes mellitus and the strategies that contribute to the improvement in adherence. Diabetes Mellitus. 2018;21(1):5–14. doi:10.14341/DM8781. In Russian.
12. Dobrynina IS, Alyokhin IO, Razvorotnev AV. Assessment of cognitive impairment in patients with diabetes type ii and their impact on adherence to therapy. Prikladnyes Informatsionnye Aspekty Meditsiny = Applied Issues of Medicine. 2019;22(1):4–9. In Russian.
13. Oganov RG, Simanenkov VI, Bakulin IG, Bakulina NV, Barbarash OL, Boytsov SA et al. Comorbidities in clinical practice. algorithms for diagnostics and treatment. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2019; 18(1):5–66. doi:10.15829/1728-8800-2019-1-5-66. In Russian.
14. Naumenko E. Diagnosis of coronary heart disease in patients with type 2 diabetes. Healthcare (Minsk). 2018;(9):38–46. In Russian.
15. Shames DV. Coronary artery restenosis risk factors in emergency or planned stenting. Vestnik Sovremennoy Klinicheskoy Meditsiny = Bulletin of Contemporary Clinical Medicine. 2019;12(4):116–123. doi:10.20969/VSKM.2019.12(4).116-123. In Russian.
16. Akhtereyev RN, Galyavich AS, Baleeva LV, Galeeva ZM. Outcomes in patients with hypertension and type 2 diabetes receiving a stent for angina. Russian Journal of Cardiology. 2020;25(4):3800. doi:10.15829/1560-4071-2020-3800. In Russian.
17. Sumin AN, Bezdenezhnykh NA, Bezdenezhnykh AV, Osokina AV, Kuzmina AA, Gruzdeva OV et al. Pre-surgery status and in-hospital complications of coronary bypass grafting in prediabetes and type 2 diabetes patients. Russian Journal of Cardiology. 2018;(5):40–48. doi:10.15829/1560-4071-2018-5-40-48. In Russian.
18. Vershinina EO, Repin AN. Predictors of long-term fatal cardiovascular events after planned percutaneous coronary interventions. Russian Journal of Cardiology. 2018;(11):34–43. doi:10.15829/1560-4071-2018-11-34-43. In Russian.
19. Kareva EN. Evolution of angiotensin receptor blockers. Klinicheskaya Farmakologiya i Terapiya = Clinical Pharmacology and Therapy. 2016;25(3):11–21. In Russian.
20. Cosentino F, Johansson I, Mellbin LG, Ostgren CJ, Linde C, Rydén L et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz486
21. Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova E et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.
22. Chazova IE, Shestakova MV, Zhernakova YuV, Markova TN, Mazurina NV, Yezhov MV et al. Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension. 2020;17(1):7–45. doi:10.26442/2075082X.2020.1.200051. In Russian.
23. Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS et al. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospectivestudy. Clin Ther. 2010;32(3):492–505. doi:10.1016/j.clinthera.2010.03.018
24. Karpov YuA, Melekhov AV. Candesartan: going beyond cardiovascular continuum. Atmosfera. News Card. 2019;(2):31–40. URL: https://rucont.ru/efd/683574 (Accessed: 06.04.2021). In Russian.
25. Rawish E, Nickel L, Schuster F, Stoelting I, Frydrychowicz A, Saar K et al. Telmisartan prevents development of obesity and normalizes hypothalamic lipid droplets. J Endocrinol. 2020;244(1): 95–110. doi:10.1530/JOE-19–0319
26. Trukhan DI. Angiotensin II receptor blockers in the treatment of arterial hypertension in patients with concomitant pathology: focus on candesartan. Systemic Hypertensions. 2014;11(3):24–29. doi:10.26442/SG29031. In Russian.
27. Leonova MV. Clinical pharmacology of angiotensin II receptor blockers: valsartan. Meditsinskiy Sovet = Medical Council. 2014;17:66–71. In Russian.
28. Bönner G, Bakris GL, Sica D, Weber MA, White WB, Perez A et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27(8):479–486. doi:10.1038/jhh.2013.6
29. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35(5):552–558. doi:10.1038/hr.2012.8
30. Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13(7):467–472. doi:10.1111/j.1751-7176.2011.00482.x
31. Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81–88. doi:10.1111/j.1751-7176.2010.00425.x
32. Troitskaya EA, Starostina ES, Kobalava ZhD. Efficacy of azilsartan medoxomil on the daily profile of peripheral and central arterial pressure and arterial stiffness in hypertensives with type 2 diabetes. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2017;16(1):74–81. doi:10.15829/1728-8800-2017-1-74-81. In Russian.
33. Chazova IE, Zhernakova YV. An international multicenter observational non-interventional prospective study of the efficacy of azilsartan medoxomil in overweight or obese patients with arterial hypertension (CONSTANT). Curr Med Res Opin. 2021;37(2):185–193. doi:10.1080/03007995.2020.1844647
34. Zhernakova YuV, Chazova IE. The possibility of a new receptor blocker to angiotensin in improving control of hypertension. Non-intervention international multicenter observational prospective study of the use azilsartan medoxomil in patients with arterial hypertension and overweight or obesity in the Russian Federation and the Republic of Kazakhstan. Systemic Hypertension. 2016;13(3):6–12. Available at: file://vozmozhnosti-novogo-blokatora-retseptorov-k-angiotenzinu-v-uluchshenii-kontrolya-arterialnoy-gipertonii-mezhdunarodnoe-mnogotsentrovoe-nablyudatelnoe-neinterven-tsionnoe-prospektivnoe-issledovanie-primeneniya-.pdf. (Accessed: 06.04.2021). In Russian.
35. Chazova IYe, Zhernakova YuV, Blinova NV, Rogoza AN. The new angiotensin II receptor blocker Edarbi as part of the pathogenetic treatment of arterial hypertension in patients with metabolic disorders. Systemic Hipertension. 2017;14(3):28–35. doi:10.26442/2075-082X_14.3.28-35. In Russian.
36. Georgiopoulos G, Katsi V, Oikonomou D. Azilsartan as a potent antihypertensive drug with possible pleiotropic cardiometabolic effects: a review study. Front Pharmacol. 2016;7:235. doi:10.3389/fphar.2016.00235
37. Nedogoda SV, Chumachek EV, Tsoma VV, Salasyuk AS, Smirnova VO, Popova EA. Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other arbs. Russian Journal of Cardiology. 2019;24(1):70–79. doi:10.15829/1560-4071-2019-1-70-79. In Russian.
38. Petrenko VI, Kubyshkin AV, Fomochkina II, Gordienko AI, Sorokina LE, Kucherenko AS. Experimental study of pathogenetic mechanisms of the metabolic syndrome at the molecular level and its correction with azilsartan. Krymskiy Zhurnal Eksperimental’noy i Klinicheskoy Meditsiny = Crimean Journal Experimental and Clinical Medicine. 2018;8(4):21–27. In Russian.
39. Kwon A, Kim GH. Single-pill combination therapy of Azilsartan Medoxomil/Chlorthalidone for treatment of hypertension: a systematic review. Clin Ther. 2020;42(7):1390–1403. doi:10.1016/j.clinthera.2020.05.015
Review
For citations:
Kochergina A.M., Barbarash O.L. Azilsartan medoxomil: opportunities and prospects in diabetes mellitus. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021;27(2):247-254. (In Russ.) https://doi.org/10.18705/1607-419X-2021-27-2-247-254
Views:
2786
Email this article 